EFFECT OF COMPREHENSIVE PHARMACOTHERAPY ON CLINICAL OUTCOMES IN CHRONIC HEART FAILURE
Keywords:
Keywords: chronic heart failure; guideline-directed medical therapy; SGLT2 inhibitor; angiotensin receptor–neprilysin inhibitor; hospitalization; mortality.Abstract
Background: Chronic heart failure (CHF) remains associated with hospitalization, functional limitation and premature mortality. Objective: To evaluate how evidence-based combination pharmacotherapy influences clinical outcomes and to identify implementation barriers. Methods: A structured narrative synthesis of pivotal randomized trials, international guidelines and relevant Uzbekistan health-system guidance was performed; no original patient cohort was enrolled. Results: Four foundational drug classes constitute guideline-directed therapy for heart failure with reduced ejection fraction (HFrEF). In DAPA-HF, the primary outcome occurred in 16.3% receiving dapagliflozin versus 21.2% on placebo; in EMPEROR-Reduced, corresponding proportions were 19.4% versus 24.7%. These outcomes reflect different trial populations and follow-up durations. Tolerability, renal function, potassium, blood pressure and access influence implementation. Conclusion: Early initiation, individualized titration and monitoring of complementary therapies improve outcomes in eligible patients, whereas findings must be distinguished by ejection fraction phenotype.
References
1.Heidenreich, P. A., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012
2.McDonagh, T. A., et al. (2023). 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 44(37), 3627–3639. https://doi.org/10.1093/eurheartj/ehad195
3.McDonagh, T. A., et al. (2021). 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368
4.McMurray, J. J. V., et al. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371, 993–1004. https://doi.org/10.1056/NEJMoa1409077
5.McMurray, J. J. V., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, 1995–2008. https://doi.org/10.1056/NEJMoa1911303
6.Packer, M., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383, 1413–1424. https://doi.org/10.1056/NEJMoa2022190
7.Solomon, S. D., et al. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387, 1089–1098. https://doi.org/10.1056/NEJMoa2206286
8.Anker, S. D., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385, 1451–1461. https://doi.org/10.1056/NEJMoa2107038
9.Mebazaa, A., et al. (2022). Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). The Lancet, 400(10367), 1938–1952. https://doi.org/10.1016/S0140-6736(22)02076-1
10.Ministry of Health of the Republic of Uzbekistan. (n.d.). Official healthcare information and national clinical guidance portal. https://gov.uz/ssv (Accessed October 16, 2026).